Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors
Journal of Thrombosis and Thrombolysis · 2024
DOI: 10.1007/s11239-024-03054-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2024. Verfasst von Anthony Dumas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA. Hauptthemen laut MEDLINE: Factor XIIa, Anticoagulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIGMS NIH HHS, NIMHD NIH HHS.
Abstract (Originalsprache)
Factor XIIa (FXIIa) is a plasma serine protease within the contact activation pathway. Inhibiting FXIIa could offer a viable therapeutic approach for achieving effective and safer anticoagulation without the bleeding risks that accompany the use of existing anticoagulants. Therefore, we investigated the anticoagulant properties of an amidine-containing molecule (inhibitor 1) to identify a potential lead molecule for subsequent development of FXIIa inhibitors. Results indicated that inhibitor 1 primarily inhibits human FXIIa with an IC50 value of ~30 µM. The inhibitor demonstrated variable selectivity against thrombin, factor IXa, factor Xa, factor XIa, and activated protein C. Michaelis-Menten kinetics indicated that the molecule is an active site inhibitor of FXIIa. Molecular modeling studies revealed that the molecule recognizes residues His57, Asp189, and Ala190 in FXIIa's active site. The inhibitor selectively and concentration-dependently prolonged the clotting time of human plasma under activated partial thromboplastin time assay conditions. The inhibitor did not exhibit significant cytotoxicity in human HEK293 cells and the in silico pharmacokinetics and toxicology data were comparable to known anticoagulants. This study introduces inhibitor 1 as a lead platform for further development as an anticoagulant to provide a more effective and safer approach to preventing and treating thromboembolic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA.
- Department of Chemistry, College of Arts and Science, Xavier University of Louisiana, New Orleans, LA, 70125, USA.
- Department of Medicinal Chemistry, College of Pharmacy, Virginia Commonwealth University, 23298, Richmond, VA, USA.
- Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA. ralhoran@xula.edu.
- Drexel Drive, College of Pharmacy, New Orleans, LA, 70125-1089, USA. ralhoran@xula.edu.
Förderung
- NHLBI NIH HHS
- NIGMS NIH HHS
- NIMHD NIH HHS
- National Institute of General Medical Sciences
- National Institute on Minority Health and Health Disparities
- National Heart, Lung, and Blood Institute
Zitieren
APA
Dumas, A., Goyal, N., Mottamal, M., Afosah, D. K., & Al-Horani, R. A. (2024). Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-024-03054-2
Vancouver
Dumas A, Goyal N, Mottamal M, Afosah DK, Al-Horani RA. Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors. Journal of Thrombosis and Thrombolysis. 2024. doi:10.1007/s11239-024-03054-2
BibTeX
@article{Dumas2024,
author = {Dumas, Anthony and Goyal, Navneet and Mottamal, Madhusoodanan and Afosah, Daniel K and Al-Horani, Rami A},
title = {Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2024},
doi = {10.1007/s11239-024-03054-2}
}
EUVIMED